
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A low neutrophil count in a child may reflect a mild condition or may be a signal of a serious disorder. Sorting out the difference between the two can avoid complications and make for a better long-term outcome.






